Compositions and method for treatment of inflammatory bowel disease
US-10603356-B2 · Mar 31, 2020 · US
Compositions and methods for treatment of protease mediated disease
US12186368B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12186368-B2 |
| Application number | US-202016825221-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 20, 2020 |
| Priority date | Jun 2, 2011 |
| Publication date | Jan 7, 2025 |
| Grant date | Jan 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method is provided for a condition related to the activity of a protease through the administration of a θ-defensin, analog, or derivative is described. Suitable proteases include metalloproteases and cysteine proteases such as Cathepsin-C. The θ-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting a metalloprotease and a cysteine protease in a subject in need thereof, comprising: injectably administering to the subject in need thereof a θ-defensin in an amount effective to inhibit the metalloprotease and the cysteine protease; wherein the θ-defensin is administered intravenously, subcutaneously, or intraperitoneally; and wherein the administration reduces TNF-alpha mediated inflammation in the subject. 2. The method of claim 1 , wherein the θ-defensin is a mini-θ-defensin. 3. The method of claim 1 , wherein the θ-defensin is selected from the group consisting of SEQ. ID NO. 8, SEQ. ID NO. 11, SEQ. ID NO. 12, SEQ. ID NO.13, SEQ. ID NO. 14, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, and SEQ. ID NO. 18. 4. The method of claim 1 , wherein the θ-defensin is selected from the group consisting of SEQ. ID NO. 8, SEQ. ID NO. 14, and SEQ. ID NO. 15. 5. The method of claim 1 , wherein the mini-θ-defensin is selected from the group consisting of SEQ. ID NO. 11, SEQ. ID NO. 12, and SEQ. ID NO.13. 6. The method of claim 1 , wherein the mini-θ-defensin is SEQ. ID NO. 12. 7. The method of claim 1 , wherein the cysteine protease is Cathepsin-C. 8. The method of claim 1 , wherein the θ-defensin is formulated for injection. 9. A method of inhibiting a metalloprotease or a cysteine protease in a subject in need thereof, comprising: administering to the subject in need thereof a θ-defensin in an amount effective to inhibit the metalloprotease or the cysteine protease, wherein the θ-defensin is a mini-θ-defensin. 10. The method of claim 9 , wherein the mini-θ-defensin is selected from the group consisting of SEQ. ID NO. 11, SEQ. ID NO. 12, and SEQ. ID NO.13. 11. The method of claim 10 , wherein the mini-θ-defensin is SEQ. ID NO. 12. 12. The method of claim 1 , wherein the θ-defensin is administered by intravenous injection. 13. The method of claim 1 , wherein the θ-defensin is administered by intravenous infusion. 14. The method of claim 1 , wherein the θ-defensin is administered by subcutaneous injection. 15. The method of claim 1 , wherein the θ-defensin is administered by intraperitoneal injection.
Assignees
Inventors
Classifications
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Cationic antimicrobial peptides, e.g. defensins · CPC title
comprising three rotors · CPC title
combined with a spraying device · CPC title
using rotating elements · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12186368B2 cover?
- A method is provided for a condition related to the activity of a protease through the administration of a θ-defensin, analog, or derivative is described. Suitable proteases include metalloproteases and cysteine proteases such as Cathepsin-C. The θ-defensin, analog, or derivative can be effectively administered parenterally, topically, or orally.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K38/10. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).